“Prognostic Value And Clinical Impact Of EBV And PDL1 Expression In Classical Hodgkin Lymphoma” (2023) Journal of Pharmaceutical Negative Results, pp. 3461–3472. doi:10.47750/pnr.2023.14.02.406.